CNTG.F Stock Overview Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Centogene N.V. Competitors Price History & Performance
Summary of share price highs, lows and changes for Centogene Historical stock prices Current Share Price US$0.12 52 Week High US$1.26 52 Week Low US$0.038 Beta -0.66 1 Month Change 11.09% 3 Month Change -38.90% 1 Year Change -89.37% 3 Year Change -97.32% 5 Year Change -98.78% Change since IPO -99.13%
Recent News & Updates Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Nov 14
Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Nov 13
Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer Oct 12
Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD) Sep 26 Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024
Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper Aug 06 See more updates Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Nov 14
Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Nov 13
Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer Oct 12
Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD) Sep 26 Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024
Take Care Before Jumping Onto Centogene N.V. (NASDAQ:CNTG) Even Though It's 36% Cheaper Aug 06
Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors Aug 02
Centogene N.V. Provides Earnings Guidance for the Year 2024 May 17
Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients May 11 Centogene N.V. announced delayed 20-F filing May 03
New minor risk - Financial data availability Mar 25
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors Feb 16
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 Jan 18
Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks Dec 21
Centogene N.V. Announces Changes to Supervisory Board Dec 18
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone Dec 14
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism Nov 15
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering Oct 11
New major risk - Revenue and earnings growth Sep 15
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023 Sep 08
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients Sep 02
Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board Aug 19
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort Jul 13 Centogene N.V. announced that it expects to receive $30 million in funding from Lifera Jun 29
New minor risk - Shareholder dilution Jun 29
Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency Jun 16
Centogene N.V., Annual General Meeting, Jun 30, 2023 Jun 14
Centogene N.V., Annual General Meeting, Jun 30, 2023 Jun 13
Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023 May 20
Full year 2022 earnings: EPS exceeds analyst expectations May 17
Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023 May 17
Centogene Regains Compliance with Nasdaq Listing Requirements Feb 08
Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH Jan 31
Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023 Jan 20
Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics Jan 12
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Dec 23
Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022 Dec 23
Centogene Receives Nasdaq Non-Compliance Notice Dec 17
Centogene N.V. Announces Changes to Supervisory Board Nov 22
Centogene Launches Rare and Neurodegenerative Disease Biodata Network Nov 04
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Jul 16
Centogene N.V. Reaffirms Earnings Guidance for the Year 2022 Jul 16
Centogene GAAP EPS of -€0.28, revenue of €10.32M Jul 15 Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director
Centogene N.V., Annual General Meeting, Jun 22, 2022 Jun 08
Centogene N.V., Annual General Meeting, Jun 22, 2022 Jun 07
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 02
Consensus forecasts updated Apr 01
Centogene N.V. Provides Earnings Guidance for the Year 2022 Mar 31 Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.
Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases Jan 05
Third quarter 2021 earnings: EPS and revenues exceed analyst expectations Nov 26
Centogene N.V. Provides Earnings Guidance for the Full Year 2021 Nov 25
Consensus forecasts updated Nov 25
Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way? Nov 25
Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020) Sep 09
Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021 Sep 09
Chief Scientific Officer Philip Lambert has left the company Aug 18
Executive Officer Richard Stoffelen has left the company Jul 01
Is Centogene (NASDAQ:CNTG) Using Debt Sensibly? Jun 29
Consensus forecasts updated Jun 23
First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020) Jun 19
Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021 Jun 17
Centogene reports Q1 results Jun 16
Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia Jun 03
Centogene N.V. Launches New CentoXome Jun 02
Centogene, Alector initiate EFRONT study in frontotemporal dementia Jun 02
Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting May 26
Centogene N.V. Extends Global Parkinson’s Disease Study May 12
Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank May 07
Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank May 06
Consensus forecasts updated Apr 24
Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019) Apr 18
Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG) Apr 17
Consensus revenue estimates increase to €137.5m Apr 16
Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study Mar 11
What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own? Mar 05 Shareholder Returns CNTG.F US Healthcare US Market 7D 1.8% -0.2% -2.2% 1Y -89.4% -9.4% 23.9%
See full shareholder returns
Return vs Industry: CNTG.F underperformed the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: CNTG.F underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CNTG.F's price volatile compared to industry and market? CNTG.F volatility CNTG.F Average Weekly Movement 62.8% Healthcare Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CNTG.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNTG.F's weekly volatility has increased from 50% to 63% over the past year.
About the Company Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.
Show more Centogene N.V. Fundamentals Summary How do Centogene's earnings and revenue compare to its market cap? CNTG.F fundamental statistics Market cap US$3.90m Earnings (TTM ) -US$36.98m Revenue (TTM ) US$50.51m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CNTG.F income statement (TTM ) Revenue €48.54m Cost of Revenue €30.84m Gross Profit €17.70m Other Expenses €53.23m Earnings -€35.53m
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) -1.23 Gross Margin 36.46% Net Profit Margin -73.21% Debt/Equity Ratio -260.1%
How did CNTG.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 17:56 End of Day Share Price 2024/12/23 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Centogene N.V. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Catherine Ramsey Schulte Baird Sung Ji Nam BTIG Erin Wilson Wright Credit Suisse
Show 4 more analysts 
